The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2275-2283

  Walker, L G ^a   Wesnes, K P ^b   Heys, S D ^a   Walker, M B ^a   Lolley, J ^a   Eremin, O ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Priory Court ^*  (United Kingdom)

Author keywords

Biological response modifier; Cognition; Interleukin 2 therapy; Mood; Psychoneuroimmunology; Psychosocial oncology

Indexed keywords

FLUOROURACIL; RECOMBINANT INTERLEUKIN 2;

ADULT; AMNESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COGNITION DISORDERS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; RECOMBINANT PROTEINS;

EID: 0030446539     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00300-0     Document Type: Article

References (18)

1. 1. Heys SD, Franks CR, Eremin O. Interleukin-2 therapy: current role in surgical oncological practice. Br J Surg 1993, 80, 155-162.
2. 2. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 1987, 107, 293-300.
3. 3. Caraceni A, martini C, Belli F, Mascheroni L, Rivoltini L, Arienti F, Cascinelli N. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 1992, 29A, 1266-1269.
4. 4. Smith MJ, Khayat D. Residual acute confusional and hallucinatory syndromes induced by Interleukin-2 and α-Interferon treatment. Psycho Oncol 1992, 1, 115-118.
5. 5. UICC (International Union Against Cancer) TNM Classification of Malignant Tumours. Berlin, Germany, 1987.
6. R. Washington, DC, American Psychiatric Press Inc., 1990.
7. 7. Wechsler D. Manual of the Wechsler Adult Intelligence Scale. New York, Psychological Corporation, 1955.
8. 8. Folstein M, Folstein S, McHugh R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975, 12, 189-198.
9. 9. Wesnes K, Simpson P, Kidd AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Human Psychopharmacol 1988, 3, 27-43.
10. 10. Baillie R, Christmas L, Price N, Restall J, Simpson PM, Wesnes K. Effects of temazepam premedication on cognitive recovery following alfentanil/propofol anaesthesia. Br J Anaesthesiol 1989, 63, 68-75.
11. 11. Simpson PM, Wesnes KA, Christmas L. A computerised system for the assessment of drug-induced performance changes in young elderly or demented patients. Br J Clin Pharmacol 1989, 27, 711P-712P.
12. 12. Wesnes K, Warburton DM. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 1984, 82, 338-342.
13. 13. McLelland GR. The effects of practice on measures of performance. Human Psychopharmacol 1987, 2, 109-118.
14. 14. Simpson M, Suirmon DJ, Wesnes KA, Wilcock GR. The cognitive drug research computerised assessment system for demented patients: a validation study. Int J Geriat Psychiat 1991, 6, 95-102.
15. 15. Saris SC, Patronas NJ, Rosenberg SA, et al. The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1988, 71, 169-174.
16. 16. Deehan DJ, Heys SD, Simpson WG, Herriot R, Broom J, Eremin O. Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 1994, 95, 366-372.
17. 17. MacMillan DN, Kernohan NM, Flett ME, Kelly P, Keys SD, Sewell HF, Walker F, Eremin O. Interleukin 2 and interleukin 2 receptors are present in human solid tumour cells in situ and in solid tumour cell lines in vitro: evidence for a direct role of the IL2/IL2R system in the regulation of tumour cell proliferation. Int J Cancer 1995, 60, 1-7.
18. 18. Denicoff KD, Durkin TM, Lotze MT, et al. The neuroendocrine effects of Interleukin-2 treatment. J Clin Endocrinol Metab 1989, 69, 402-410.